# Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock

> **NCT00816790** · PHASE4 · TERMINATED · sponsor: **Fraser Health** · enrollment: 20 (estimated)

## Conditions studied

- Septic Shock
- Acute Renal Failure

## Interventions

- **DRUG:** Piperacillin/Tazobactam
- **DRUG:** Piperacillin/Tazobactam

## Key facts

- **NCT ID:** NCT00816790
- **Lead sponsor:** Fraser Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Study stopped because of study personel movement to another institution.
- **Last updated:** 2015-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00816790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00816790, "Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00816790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*